Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive mice

European Journal of Pharmacology

Volumn 402, Issue 3, 2000, Pages 241-246

  Rasmussen, Thøger ^a   Sauerberg, Per ^a   Nielsen, Erik B ^a   Swedberg, Michael D B ^a   Thomsen, Christian ^a   Sheardown, Malcolm J ^a   Jeppesen, Lone ^a   Calligaro, David O ^b   Delapp, Neil W ^b   Whitesitt, Celia ^b   Ward, John S ^b   Shannon, Harlan E ^b   Bymaster, Frank P ^b   Fink Jensen, Anders ^a  

^a NOVO NORDISK A S   (Denmark)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

(Mouse); Cocaine; Drug naive; Muscarinic receptor agonist; Self administration

Indexed keywords

6 (3 PROPYLTHIO 1,2,5 THIADIAZOL 4 YL) 1 AZABICYCLO[3.2.1]OCTANE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; COCAINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; MUSCARINIC AGENT; MUSCARINIC RECEPTOR; OLANZAPINE; OXOTREMORINE; PILOCARPINE; RISPERIDONE; SCOPOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SELF ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BICYCLO COMPOUNDS; COCAINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MUSCARINIC AGONISTS; OXOTREMORINE; PILOCARPINE; SELF ADMINISTRATION; THIADIAZOLES;

EID: 0034714293     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00442-8     Document Type: Article

References (19)

1. Bymaster F., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
2. Bymaster F.P., Shannon H.E., Rasmussen K., DeLapp N.W., Mitch C.H., Ward J.S., Calligaro D.O., Ludvigsen T.S., Sheardown M.J., Olesen P.H., Swedberg M.D., Sauerberg P., Fink-Jensen A. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R) 6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane. Eur. J. Pharmacol. 356:1998;109-119.
3. Bymaster F.P., Shannon H.E., Rasmussen K., DeLapp N.W., Ward J.S., Calligaro D.O., Mitch C.H., Whitesitt C., Ludvigsen T.S., Sheardown M.J., Swedberg M.D.B., Rasmussen T., Olesen P.H., Jeppesen L., Sauerberg P., Fink-Jensen A. Potential role of muscarinic receptors in schizophrenia. Life Sci. 64:1999;527-534.
4. Chapman C.A., Yeomans J.S., Blaha C.D., Blackburn J.R. Increased striatal dopamine efflux follows scopolamine administered systemically or to the tegmental pedunculopontine nucleus. Neuroscience. 76:1997;177-186.
5. Di Chiara G., Morelli M., Silvana C. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. TINS. 17:1994;228-233.
6. Fink-Jensen A., Kristensen P., Shannon H.E., Calligaro D.O., Delapp N.W., Whitesitt C., Ward J.S., Thomsen C., Rasmussen T., Sheardown M.J., Jeppesen L., Sauerberg P., Bymaster F. Muscarinic agonists exhibit functional antagonism in unilaterally 6-OHDA lesioned rats. NeuroReport. 9:1998;3481-3486.
7. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13:1992;177-184.
8. Rasmussen T., Fink-Jensen A. Intravenous scopolamine is potently self-administered in drug-naive mice. Neuropsychopharmacology. 22:1900;97-99.
9. Rasmussen T., Swedberg M.D.B. Reinforcing effects of nicotinic compounds: Intravenous self-administration in drug-naive mice. Pharmacol. Biochem. Behav. 60:1998;567-573.
10. Rasmussen T., Nielsen E.B., Fink-Jensen A. Cocaine self-administration in drug-naive mice is inhibited by typical and atypical antipsychotics. Soc. Neurosci. Abstr. 24:1998;2169.
11. Rasmussen T., Swedberg M.D.B., Bymaster F.P. Olanzapine: antidopaminergic and memory effects in mice. Schizophrenia Res. 29(12):1998;166.
12. Richards M.H., Van Giersbergen P.L.M. Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists. Br. J. Pharmacol. 114:1995;1241-1249.
13. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J. Jr., Shen Y., Meltzer H.Y., Sibley D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 268:1994;1403-1410.
14. Sauerberg P., Jeppesen L., Olesen P.H., Rasmussen T., Swedberg M.D.B., Sheardown M., Fink-Jensen A., Thomsen T., Thøgersen H., Rimwall K., Ward J.S., Calligaro D.O., DeLapp N.W., Bymaster F.P., Shannon H.E. Muscarinic agonists with antipsychotic activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity. J. Med. Chem. 41:1998;4378-4384.
15. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Vangompel P., Lesage A.S., Deloore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs- in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
16. Schwarz R.D., Davis R.E., Jaen J.C., Spencer C.J., Tecle H., Thomas A.J. Characterization of muscarinic agonists in recombinant cell lines. Life Sci. 52:1993;465-472.
17. Shannon H.E., Hart J.C., Bymaster F.P., Calligaro D.O., DeLapp N.W., Mitch C.H., Ward J.S., Fink-Jensen A., Sauerberg P., Jeppesen L., Sheardown M.J., Swedberg M.D.B. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance in rats. J. Pharmacol. Exp. Ther. 290:1999;901-907.
18. Wang J.Q., McGinty J.F. Muscarinic receptors regulate striatal neuropeptide gene expression in normal and amphetamine-treated rats. Neuroscience. 75:1996;43-66.
19. Yeomans J.S. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology. 12:1995;3-16.